Xvivo Perfusion AB (STU:3XV)
€ 38 0.65 (1.74%) Market Cap: 1.21 Bil Enterprise Value: 1.17 Bil PE Ratio: 119.73 PB Ratio: 6.25 GF Score: 82/100

Q3 2021 Xvivo Perfusion AB Earnings Call Transcript

Oct 21, 2021 / 12:00PM GMT
Release Date Price: €33 (-10.57%)
Operator

Ladies and gentlemen, welcome to the XVIVO Group Interim Report Q3 2021. I will now hand over to Dag Andersson, CEO. Sir, please go ahead.

Dag Andersson;publ;President;CEO
Xvivo Perfusion AB

()-&

So hello, everybody. Good morning, good afternoon, good evening, depending on where you are in the world. Today, Kristoffer Nordstrom, CFO; and myself, Dag Andersson, CEO, we are happy to present the Q3 numbers and report to you, and you will be able to ask questions. And also on the web, there will be possibility to post those questions.

So if we look at some of the highlights during the third quarter, we had an increase of 31% net sales, acquired growth. As you probably remember, we made an acquisition in the Netherlands end of September last year when we acquired the Dutch company, Organ Assist. We have had a good increase also in terms of machine perfusion, percentage of net sales at 53%. Gross margins continue to be strong. We have a gross margin of 78% for Thoracic; for Abdominal, 53%, which is actually

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot